Company intelligence / Profile preview

Shanghai Hongcheng Network Technology

上海市（Shanghai）, 上海市（Shanghai）, 中国（China）hong-cheng.cn ↗

Ownership: Private
Development stage: Other

Overview

Shanghai Hongcheng Pharmaceutical has several programs in early clinical development, with at least two Phase 1 trials ongoing as of May 2025. The company focuses on innovative biologics such as monoclonal antibodies and trispecific antibodies targeting cancer and immune-related indications. No late-stage or approved products are reported yet.

Therapeutic areas: NeurologyInfectious DiseasesDermatologyOncologyImmunology
Modalities: Monoclonal antibodyTrispecific antibodyAntibody-drug conjugateBiological productSmall molecule drug
Industry: Biotech

Partnerships

No major pharmaceutical partnerships publicly disclosed.

Beyond the preview

Go deeper on Shanghai Hongcheng Network Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Hongcheng Network Technology.

Explore the full profile